NCT00652106

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 432 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the safety and efficacy of brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution compared with concurrent brimonidine 0.2% and timolol ophthalmic solutions

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution	0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
DRUG	Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution	Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
DRUG	Brimonidine 0.2% ophthalmic solution	Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)

Timeline

• Start date: 2003-06-01
• Primary completion: 2004-03-01
• Completion: 2004-03-01
• First posted: 2008-04-03
• Last updated: 2008-04-03

Locations

1 site across 1 country: United States